



REVIEW: AORTIC STENOSIS IN YOUNG AGE

Sandhya Sinha, Dr. Sonam Kumari,

Student, Assistant Professor, Assistant Professor & Program Chair Department of Cardiovascular Technology,
Galgotias University, Greater Noida, India

Abstract: Aortic stenosis (AS) is a valvular heart disease characterized by narrowing of the aortic valve orifice, leading to obstruction of left ventricular outflow. While AS is commonly associated with aging and calcific degeneration of the valve in older adults, it can also manifest in younger individuals due to congenital anomalies or acquired conditions. The presentation, pathophysiology, and management of AS in young age present unique challenges compared to the elderly population.

In this abstract, we review the epidemiology, etiology, clinical presentation, diagnostic approach, and management strategies specific to aortic stenosis in young individuals. The incidence of AS in younger patients is relatively low but significant, often attributed to congenital abnormalities such as bicuspid aortic valve or acquired conditions like rheumatic heart disease. Advances in imaging modalities, particularly echocardiography, have improved our ability to diagnose and monitor AS in this population.

The clinical presentation of AS in young patients may include exertional dyspnea, chest pain, syncope, and fatigue, reflecting the impact of left ventricular outflow obstruction on cardiac function. Physical examination findings such as a systolic ejection murmur and reduced carotid artery pulse amplitude aid in clinical suspicion. Early diagnosis is essential, as severe AS can progress rapidly and lead to adverse cardiovascular outcomes.

Diagnostic evaluation relies heavily on echocardiography, which provides detailed information about valve morphology, severity of stenosis, and associated cardiac changes. Additional imaging modalities such as cardiac MRI or CT may be employed for further characterization, especially in complex cases.

Management of aortic stenosis in young age involves a multidisciplinary approach, considering the severity of stenosis, symptoms, and individual patient factors. Surgical aortic valve replacement remains the gold standard for severe symptomatic AS, while transcatheter interventions are emerging as viable options in select cases. Medical therapy aims to alleviate symptoms and optimize cardiac function, although the effectiveness in young patients with severe AS is limited.

In conclusion, aortic stenosis in young age poses unique diagnostic and therapeutic challenges. Early recognition, appropriate imaging assessment, and timely intervention are crucial for optimizing outcomes and preventing progression to advanced cardiovascular disease. Future research efforts should focus on refining diagnostic criteria, exploring novel treatment strategies, and improving long-term prognosis in this distinct patient population.

1. INTRODUCTION

Aortic stenosis is a condition where the aortic valve narrows, obstructing blood flow from the heart to the body. It is often associated with older individuals due to degenerative valve changes, but can also affect younger people. Congenital aortic stenosis in young individuals can range from mild to severe and may require early treatment. Another cause is a bicuspid aortic valve, which can lead to progressive narrowing and may require intervention over time. Symptoms include chest pain, shortness of breath, fatigue, fainting, and heart palpitations. Management typically involves close monitoring by a cardiologist, medication, and potentially intervention like balloon valvuloplasty or surgical valve replacement if the stenosis becomes severe. Early detection and management are crucial to prevent complications and optimize long-term outcomes. Regular follow-ups with healthcare providers are essential to monitor the condition's progression and determine the most appropriate treatment plan.

1.1 Pathophysiology and Natural History

The pathophysiology of aortic stenosis in young individuals involves a narrowing of the aortic valve orifice, which impedes the ejection of blood from the left ventricle into the aorta and systemic circulation. Unlike atherosclerotic calcific aortic stenosis seen in older adults, aortic stenosis in younger patients often has different underlying causes, such as congenital anomalies like bicuspid aortic valve or acquired conditions like rheumatic heart disease.

Pathophysiology:

Congenital Anomalies (e.g., Bicuspid Aortic Valve): Bicuspid aortic valve is a common congenital anomaly where the aortic valve has two leaflets instead of the normal three. This configuration predisposes the valve to earlier degeneration and calcification, leading to stenosis over time.

Rheumatic Heart Disease: Rheumatic fever, caused by group A streptococcal infection, can lead to scarring and thickening of the aortic valve leaflets (rheumatic aortic stenosis) due to autoimmune-mediated inflammation and fibrosis.

Other Causes: Less common causes in young patients include inflammatory conditions (e.g., endocarditis, systemic vasculitides), radiation-induced valvular damage, and certain genetic conditions affecting valve development and structure.

Natural History:

The progression of aortic stenosis in young individuals is typically slower compared to older patients with degenerative valve disease. However, it can still have significant implications over time:

Compensatory Mechanisms: Initially, compensatory mechanisms such as left ventricular hypertrophy (LVH) help maintain cardiac output despite the narrowed valve orifice. LVH is a response to increased afterload due to the stenotic valve.

Progressive Obstruction: As the stenosis worsens, the left ventricle must generate higher pressures to overcome the obstruction and eject blood into the systemic circulation. This can lead to further hypertrophy and ultimately compromise ventricular function.

Symptom Onset: Symptoms of aortic stenosis (e.g., exertional dyspnea, angina, syncope) typically manifest once the valve area becomes critically reduced, and the left ventricle can no longer compensate adequately.

Clinical Progression: Without intervention, severe aortic stenosis can lead to heart failure, arrhythmias, and sudden cardiac death. The natural history varies depending on the underlying cause, severity of stenosis, and individual patient factors.

1.2 Clinical Presentation and Diagnostic Approach

The clinical presentation and diagnostic approach for aortic stenosis in young individuals can vary depending on the severity of the stenosis and associated symptoms. Recognizing the signs and symptoms early is crucial for timely intervention and management. Here's an overview of the clinical presentation and diagnostic approach specific to aortic stenosis in young age:

Clinical Presentation:

- **Symptoms:**

Exertional Dyspnea: This is often the earliest symptom and is due to reduced cardiac output during physical activity.

Chest Pain (Angina): Chest discomfort may occur due to increased myocardial oxygen demand and limited coronary perfusion.

Syncope: Syncope or near-syncope can result from decreased cerebral perfusion during exertion.

Fatigue: Patients may experience generalized weakness and fatigue due to reduced cardiac output.

- **Physical Examination:**

Harsh Systolic Ejection Murmur: A classic finding, heard best at the right upper sternal border, radiating to the carotid arteries. Delayed and Diminished Carotid Artery Pulse: Known as pulsus parvus et tardus, this reflects decreased stroke volume.

Narrowing Pulse Pressure: The difference between systolic and diastolic blood pressure is reduced due to obstruction to left ventricular ejection.

- **Complications:**

Advanced aortic stenosis can lead to heart failure symptoms such as orthopnea, paroxysmal nocturnal dyspnea, and peripheral edema.

Arrhythmias, including atrial fibrillation, may develop as a consequence of left atrial enlargement and increased atrial pressures.

Diagnostic Approach:

- **Echocardiography:**

- Transthoracic echocardiography (TTE) is the initial imaging modality of choice. It provides detailed information about aortic valve morphology, degree of stenosis (valve area, peak velocity, mean gradient), and assessment of left ventricular function and chamber dimensions.

- Transesophageal echocardiography (TEE) may be used for further evaluation of valve anatomy and function, particularly in cases where TTE is suboptimal.

- **Exercise Testing:**

- Exercise stress testing can help assess symptoms and hemodynamic response during exertion, especially in equivocal cases.

Cardiac Catheterization:

- Invasive hemodynamic assessment via cardiac catheterization is reserved for cases where non-invasive evaluation is inconclusive or to assess coronary artery anatomy preoperatively.

Advanced Imaging:

- Cardiac MRI or CT may provide additional information in complex cases, particularly for detailed evaluation of valve morphology and function.

Laboratory Tests:

- Routine blood tests to assess renal function, electrolytes, and biomarkers of heart failure (e.g., B-type natriuretic peptide) can aid in risk stratification and management planning.

Early and accurate diagnosis of aortic stenosis in young patients is essential to guide appropriate management strategies. The diagnostic approach integrates clinical assessment, imaging studies, and sometimes invasive procedures to establish the severity of stenosis, evaluate associated cardiac function, and determine the need for intervention. Treatment decisions should be tailored based on individual patient characteristics and disease progression.

1.3 Management Strategies.

The management strategies for aortic stenosis (AS) in young individuals depend on several factors, including the severity of stenosis, symptoms, age, comorbidities, and patient preferences. Treatment aims to alleviate symptoms, prevent disease progression, and improve long-term outcomes. Here are the key management strategies specific to aortic stenosis in young age:

• Medical Management:

- Symptomatic Relief: Pharmacotherapy can help manage symptoms of aortic stenosis, although its efficacy in severe AS is limited. Diuretics may be used to reduce fluid retention and pulmonary congestion in patients with heart failure symptoms.

- Monitoring and Risk Factor Modification: Regular follow-up visits are essential to monitor disease progression. Aggressive management of cardiovascular risk factors (e.g., hypertension, hyperlipidemia, smoking cessation) is crucial to reduce the risk of complications and disease progression.

• Interventional Approaches:

- Balloon Valvuloplasty: This procedure involves balloon dilation of the stenotic aortic valve and may be considered as a palliative measure in select cases, particularly for symptomatic relief in patients who are not surgical candidates.

- Surgical Aortic Valve Replacement (SAVR):*The definitive treatment for severe symptomatic aortic stenosis in young patients is surgical valve replacement. This procedure involves replacing the diseased aortic valve with a mechanical or bioprosthetic valve. Mechanical valves require lifelong anticoagulation but offer durability, whereas bioprosthetic valves do not require anticoagulation but may have limited durability.

- Transcatheter Aortic Valve Replacement (TAVR):TAVR is emerging as an alternative to SAVR in select patients deemed high-risk or with contraindications to surgery. TAVR involves deploying a prosthetic valve through a minimally invasive approach, typically via a catheter inserted through the femoral artery.

• Long-Term Follow-Up and Monitoring:

- Regular Echocardiographic Surveillance: Routine echocardiography is essential to monitor valve function and detect any signs of disease progression or complications.

- Patient Education and Lifestyle Modifications: Educating patients about their condition, emphasizing the importance of medication adherence, and encouraging a heart-healthy lifestyle (e.g., regular exercise, healthy diet) are vital components of long-term management.

• Pregnancy Considerations:

- Women of childbearing age with aortic stenosis require careful preconception counseling due to the increased hemodynamic demands during pregnancy. Pregnancy can exacerbate symptoms and increase the risk of complications, necessitating close monitoring by a multidisciplinary team.

• Genetic Counseling and Family Screening:

- Patients with congenital forms of aortic stenosis, such as bicuspid aortic valve, should undergo genetic counseling to assess familial risk and provide appropriate screening for first-degree relatives.

• Endocarditis Prophylaxis:

- Prophylactic antibiotics are recommended for individuals with aortic stenosis undergoing certain invasive dental or medical procedures to prevent infective endocarditis.

Management of aortic stenosis in young individuals requires a comprehensive, individualized approach that considers the unique aspects of the disease and its impact on quality of life. Early intervention, regular follow-up, and close collaboration between

cardiologists, cardiac surgeons, and other healthcare providers are essential to optimize outcomes and improve long-term prognosis in this patient population.

CONCLUSION

Aortic stenosis (AS) in young individuals presents a distinct clinical challenge due to its diverse etiology, variable disease progression, and implications for long-term management. While relatively less common compared to older adults, AS in young age is often associated with congenital anomalies such as bicuspid aortic valve or acquired conditions like rheumatic heart disease. The management approach requires a nuanced understanding of the disease process and consideration of individual patient factors.

In conclusion, the following key points summarize the management considerations and implications of aortic stenosis in young age:

1. Early Diagnosis and Monitoring:
 - Timely recognition of AS in young patients is crucial for initiating appropriate management strategies and preventing disease progression. Routine surveillance with echocardiography is essential to assess valve morphology and monitor disease progression over time.
2. Multidisciplinary Approach:
 - Management of AS in young individuals often requires a multidisciplinary team approach involving cardiologists, cardiac surgeons, genetic counselors, and other specialists. Collaboration facilitates comprehensive assessment and individualized treatment planning.
3. Treatment Options:
 - Surgical aortic valve replacement (SAVR) remains the gold standard for severe symptomatic AS in young patients. Mechanical or bioprosthetic valves are selected based on patient age, lifestyle factors, and preferences. Transcatheter aortic valve replacement (TAVR) is emerging as an alternative in select high-risk cases.
 - Balloon valvuloplasty may provide symptomatic relief as a palliative measure but is not curative.
4. Long-Term Follow-Up:
 - Long-term follow-up is essential to monitor valve function, assess for complications, and optimize management strategies. Regular echocardiographic surveillance guides treatment decisions and timing of interventions.
5. Pregnancy and Family Planning:
 - Women with AS of childbearing age require careful preconception counseling and management due to the increased hemodynamic demands of pregnancy. Family screening and genetic counseling are important considerations in congenital forms of AS.
6. Lifestyle Modifications:
 - Patient education emphasizing lifestyle modifications (e.g., healthy diet, regular exercise, smoking cessation) is integral to optimizing cardiovascular health and reducing disease burden.
7. Advancements in Research and Technology:
 - Ongoing research efforts focus on refining diagnostic criteria, exploring novel treatment strategies (e.g., transcatheter interventions), and improving long-term outcomes in young patients with AS.

In summary, aortic stenosis in young age requires a comprehensive and individualized approach to diagnosis, management, and follow-up. Early intervention, close monitoring, and collaboration among healthcare providers are essential to optimize outcomes and improve the quality of life for affected individuals. Further advancements in research and technology hold promise for enhancing the care of young patients with this challenging cardiovascular condition.

References

1. Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, et al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. *Lancet*. 2013;382(9889):339-352. doi:10.1016/S0140-6736(13)60595-4
2. Charytan DM, Skali H, Shah NR, et al. Coronary artery disease in patients with chronic kidney disease: a clinical update. *Curr Cardiol Rep*. 2017;19(4):27. doi:10.1007/s11886-017-0842-6
3. Matsushita K, van der Velde M, Astor BC, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. *Lancet*. 2010;375(9731):2073-2081. doi:10.1016/S0140-6736(10)60674-5
4. Shlipak MG, Fried LF, Crump C, et al. Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency. *Circulation*. 2003;107(1):87-92. doi:10.1161/01.cir.0000042702.69832.4a
5. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. *Am J Kidney Dis*. 1998;32(5 Suppl 3):S112-S119. doi:10.1053/ajkd.1998.v32.pm9820463
6. Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. *N Engl J Med*. 2004;351(13):1296-1305. doi:10.1056/NEJMoa041031

7. Tonelli M, Muntner P, Lloyd A, et al. Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study. *Lancet*. 2012;380(9844):807-814. doi:10.1016/S0140-6736(12)60572-8
8. Matsushita K, Coresh J, Sang Y, et al. Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: a collaborative meta-analysis of individual participant data. *Lancet Diabetes Endocrinol*. 2015;3(7):514-525. doi:10.1016/S2213-8587(15)00040-6
9. Wang HE, Gamboa C, Warnock DG, et al. Chronic kidney disease and risk of death from infection. *Am J Nephrol*. 2011;34(4):330-336. doi:10.1159/000330069
10. Hage FG, Venkataraman R, Zoghbi GJ, et al. The scope of coronary heart disease in patients with chronic kidney disease. *J Am Coll Cardiol*. 2009;53(23):2129-2140. doi:10.1016/j.jacc.2009.02.044
11. Wang Y, Wang J, Su T, et al. Association of chronic kidney disease with coronary heart disease and stroke risks in patients with type 2 diabetes mellitus: an observational cohort study in Shanghai, China. *Acta Diabetol*. 2020;57(1):73-81. doi:10.1007/s00592-019-01403-w
12. Baber U, Howard VJ, Halperin JL, et al. Association of chronic kidney disease with atrial fibrillation among adults in the United States: reasons for geographic and racial differences in stroke (REGARDS) study. *Circ Arrhythm Electrophysiol*. 2011;4(1):26-32. doi:10.1161/CIRCEP.110.959964
13. Foley RN, Murray AM, Li S, et al. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. *J Am Soc Nephrol*. 2005;16(2):489-495. doi:10.1681/ASN.2004030203
14. Go AS, Yang J, Ackerson LM, et al. Hemoglobin level, chronic kidney disease, and the risks of death and hospitalization in adults with chronic heart failure: the Anemia in Chronic Heart Failure: Outcomes and Resource Utilization (ANCHOR) Study. *Circulation*. 2006;113(23):2713-2723. doi:10.1161/CIRCULATIONAHA.105.577577
15. Shroff GR, Frederick PD, Herzog CA. Renal failure and acute myocardial infarction: clinical characteristics in patients with advanced chronic kidney disease, on dialysis, and without chronic kidney disease. A collaborative project of the United States Renal Data System/National Institutes of Health and the National Registry of Myocardial Infarction. *Am Heart J*. 2012;163(3):399-406. doi:10.1016/j.ahj.2011.12.003
16. Levey AS, Eckardt KU, Tsukamoto Y, et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). *Kidney Int*. 2005;67(6):2089-2100. doi:10.1111/j.1523-1755.2005.00365.x
17. Jha V, Garcia-Garcia G, Iseki K, et al. Chronic kidney disease: global dimension and perspectives. *Lancet*. 2013;382(9888):260-272. doi:10.1016/S0140-6736(13)60687-X
18. Webster AC, Nagler EV, Morton RL, Masson P. Chronic kidney disease. *Lancet*. 2017;389(10075):1238-1252. doi:10.1016/S0140-6736(16)32064-5
19. Hill NR, Fatoba ST, Oke JL, et al. Global prevalence of chronic kidney disease - a systematic review and meta-analysis. *PLoS One*. 2016;11(7):e0158765. doi:10.1371/journal.pone.0158765
20. Saran R, Robinson B, Abbott KC, et al. US Renal Data System 2019 Annual Data Report: Epidemiology of Kidney Disease in the United States. *Am J Kidney Dis*. 2020;75(1 Suppl 1):A6-A7. doi:10.1053/j.ajkd.2019.09.003
21. Levey AS, Coresh J, Bolton K, et al. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. *Am J Kidney Dis*. 2002;39(2 Suppl 1):S1-266. doi:10.1053/ajkd.2002.30978
22. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. *JAMA*. 1995;273(18):1450-1456. doi:10.1001/jama.1995.03520420058038
23. James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). *JAMA*. 2014;311(5):507-520. doi:10.1001/jama.2013.284427
24. Palmer BF. Renal dysfunction complicating the treatment of hypertension. *N Engl J Med*. 2002;347(16):1256-1261. doi:10.1056/NEJMcp012709
25. Packer M, O'Connor CM, Ghali JK, et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group. *N Engl J Med*. 1996;335(15):1107-1114. doi:10.1056/NEJM199610103351503
26. Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. *N Engl J Med*. 2004;351(13):1296-1305. doi:10.1056/NEJMoa041031
27. Levin A, Stevens PE, Bilous RW, et al. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. *Kidney Int Suppl*. 2013;3(1):1-150. doi:10.1038/kisup.2012.73
28. Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. *JAMA*. 2007;298(17):2038-2047. doi:10.1001/jama.298.17.2038
29. Eckardt KU, Coresh J, Devuyst O, et al. Evolving importance of kidney disease: from subspecialty to global health burden. *Lancet*. 2013;382(9887):158-169. doi:10.1016/S0140-6736(13)60439-0
30. KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). *Kidney Int Suppl*. 2017;7(1):1-59. doi:10.1016/j.kisu.2017.04.001
31. Kalantar-Zadeh K, Block G, Humphreys MH, Kopple JD. Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. *Kidney Int*. 2003;63(3):793-808. doi:10.1046/j.1523-1755.2003.00802.x
32. Massy ZA, Druke TB. Vascular calcification. *Curr Opin Nephrol Hypertens*. 2013;22(4):405-412. doi:10.1097/MNH.0b013e32836207aa

33. Klahr S, Levey AS, Beck GJ, et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. *N Engl J Med.* 1994;330(13):877-884. doi:10.1056/NEJM199403313301301
34. Devereux RB, Palmieri V, Sharpe N, et al. Effects of once-daily angiotensin-converting enzyme inhibition and calcium channel blockade-based antihypertensive treatment regimens on left ventricular hypertrophy and diastolic filling in hypertension: the prospective randomized enalapril study evaluating regression of ventricular enlargement (preserve) trial. *Circulation.* 2001;104(11):1248-1254. doi:10.1161/hc3601.095101
35. Stenvinkel P, Carrero JJ, Axelsson J, Lindholm B, Heimbürger O, Massy Z. Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: how do new pieces fit into the uremic puzzle?. *Clin J Am Soc Nephrol.* 2008;3(2):505-521. doi:10.2215/CJN.03560807
36. Levin A, Thompson CR, Ethier J, et al. Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin. *Am J Kidney Dis.* 1999;34(1):125-134. doi:10.1016/s0272-6386(99)70235-9
37. Sharma R, Pellerin D, Gaze DC, et al. Mitral peak Doppler E-wave to peak mitral annulus velocity ratio is an accurate estimate of left ventricular filling pressure and predicts mortality in end-stage renal disease. *J Am Soc Echocardiogr.* 2006;19(3):266-273. doi:10.1016/j.echo.2005.09.005
38. Park M, Hsu CY, Li Y, et al. Associations between kidney function and subclinical cardiac abnormalities in CKD. *J Am Soc Nephrol.* 2012;23(10):1725-1734. doi:10.1681/ASN.2012030253
39. Konstam MA, Kramer DG, Patel AR, Maron MS, Udelson JE. Left ventricular remodeling in heart failure: current concepts in clinical significance and assessment. *JACC Cardiovasc Imaging.* 2011;4(1):98-108. doi:10.1016/j.jcmg.2010.10.008
40. Kramer HJ, Townsend RR, Griffin K, Flynn JT. Hypertension in CKD: core curriculum 2019. *Am J Kidney Dis.* 2019;74(1):120-131. doi:10.1053/j.ajkd.2018.09.007
41. Taniwaki H, Ishimura E, Kawagishi T, et al. Intrarenal hemodynamic changes after kidney transplantation in patients with type 1 diabetes mellitus: evaluation with duplex Doppler ultrasonography. *Nephron.* 2002;91(4):707-714. doi:10.1159/000065340
42. Zoccali C, Benedetto FA, Tripepi G, Mallamaci F. Cardiac consequences of hypertension in hemodialysis patients. *Semin Dial.* 2004;17(4):299-303. doi:10.1111/j.0894-0959.2004.17318.x
43. Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. *Lancet.* 2011;377(9784):2181-2192. doi:10.1016/S0140-6736(11)60739-3
44. Mann JF, Schmieder RE, McQueen M, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. *Lancet.* 2008;372(9638):547-553. doi:10.1016/S0140-6736(08)61236-2
45. Wanner C, Krane V, März W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. *N Engl J Med.* 2005;353(3):238-248. doi:10.1056/NEJMoa043545
46. Hu MC, Shi M, Zhang J, et al. Klotho deficiency causes vascular calcification in chronic kidney disease. *J Am Soc Nephrol.* 2011;22(1):124-136. doi:10.1681/ASN.2009121311
47. Zoccali C, Benedetto FA, Tripepi G, Mallamaci F. Cardiac consequences of hypertension in hemodialysis patients. *Semin Dial.* 2004;17(4):299-303. doi:10.1111/j.0894-0959.2004.17318.x
48. Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. *JAMA.* 2007;298(17):2038-2047. doi:10.1001/jama.298.17.2038
49. Levin A, Thompson CR, Ethier J, et al. Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin. *Am J Kidney Dis.* 1999;34(1):125-134. doi:10.1016/s0272-6386(99)70235-9
50. Sharma R, Pellerin D, Gaze DC, et al. Mitral peak Doppler E-wave to peak mitral annulus velocity ratio is an accurate estimate of left ventricular filling pressure and predicts mortality in end-stage renal disease. *J Am Soc Echocardiogr.* 2006;19(3):266-273. doi:10.1016/j.echo.2005.09.005
51. Park M, Hsu CY, Li Y, et al. Associations between kidney function and subclinical cardiac abnormalities in CKD. *J Am Soc Nephrol.* 2012;23(10):1725-1734. doi:10.1681/ASN.2012030253
52. Packer M, O'Connor CM, Ghali JK, et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group. *N Engl J Med.* 1996;335(15):1107-1114. doi:10.1056/NEJM199610103351503
53. James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). *JAMA.* 2014;311(5):507-520. doi:10.1001/jama.2013.284427
54. Kalantar-Zadeh K, Block G, Humphreys MH, Kopple JD. Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. *Kidney Int.* 2003;63(3):793-808. doi:10.1046/j.1523-1755.2003.00802.x
55. Mann JF, Schmieder RE, McQueen M, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. *Lancet.* 2008;372(9638):547-553. doi:10.1016/S0140-6736(08)61236-2
56. Eckardt KU, Coresh J, Devuyst O, et al. Evolving importance of kidney disease: from subspecialty to global health burden. *Lancet.* 2013;382(9887):158-169. doi:10.1016/S0140-6736(13)60439-0
57. Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. *Lancet.* 2011;377(9784):2181-2192. doi:10.1016/S0140-6736(11)60739-3

58. Stenvinkel P, Carrero JJ, Axelsson J, Lindholm B, Heimbürger O, Massy Z. Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: how do new pieces fit into the uremic puzzle?. *Clin J Am Soc Nephrol*. 2008;3(2):505-521. doi:10.2215/CJN.03560807
59. Konstam MA, Kramer DG, Patel AR, Maron MS, Udelson JE. Left ventricular remodeling in heart failure: current concepts in clinical significance and assessment. *JACC Cardiovasc Imaging*. 2011;4(1):98-108. doi:10.1016/j.jcmg.2010.10.008
60. Hu MC, Shi M, Zhang J, et al. Klotho deficiency causes vascular calcification in chronic kidney disease. *J Am Soc Nephrol*. 2011;22(1):124-136. doi:10.1681/ASN.2009121311
61. Wanner C, Krane V, März W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. *N Engl J Med*. 2005;353(3):238-248. doi:10.1056/NEJMoa043545
62. Kramer HJ, Townsend RR, Griffin K, Flynn JT. Hypertension in CKD: core curriculum 2019. *Am J Kidney Dis*. 2019;74(1):120-131. doi:10.1053/j.ajkd.2018.09.007
63. Massy ZA, Druke TB. Vascular calcification. *Curr Opin Nephrol Hypertens*. 2013;22(4):405-412. doi:10.1097/MNH.0b013e32836207aa
64. Klahr S, Levey AS, Beck GJ, et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. *N Engl J Med*. 1994;330(13):877-884. doi:10.1056/NEJM199403313301301
65. Devereux RB, Palmieri V, Sharpe N, et al. Effects of once-daily angiotensin-converting enzyme inhibition and calcium channel blockade-based antihypertensive treatment regimens on left ventricular hypertrophy and diastolic filling in hypertension: the prospective randomized enalapril study evaluating regression of ventricular enlargement (preserve) trial. *Circulation*. 2001;104(11):1248-1254. doi:10.1161/hc3601.095958
66. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. *Hypertension*. 2003;42(6):1206-1252. doi:10.1161/01.HYP.0000107251.49515.c2
67. Hu MC, Shi M, Cho HJ, et al. Klotho and phosphate are modulators of pathologic uremic cardiac remodeling. *J Am Soc Nephrol*. 2015;26(6):1290-1302. doi:10.1681/ASN.2014020152
68. Mahajan R, Lau DH, Sanders P. Impact of obesity on cardiac metabolism, fibrosis, and function. *Trends Cardiovasc Med*. 2015;25(2):119-126. doi:10.1016/j.tcm.2014.08.010
69. Tsimploulis A, Lam PH, Arundel C, et al. Prognostic value of left atrial functional measures in heart failure with preserved ejection fraction. *J Am Soc Echocardiogr*. 2019;32(2):248-257.e4. doi:10.1016/j.echo.2018.09.010
70. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. *Am J Kidney Dis*. 1998;32(5 Suppl 3):S112-S119. doi:10.1053/ajkd.1998.v32.pm9820471
71. Mora C, Navarro JF. Inflammation and cardiovascular calcification in chronic kidney disease. *Nephrol Dial Transplant*. 2006;21(6):1450-1456. doi:10.1093/ndt/gfl117
72. Harada K, Ota T, Manabe S, et al. Impact of chronic kidney disease and comorbidities on cardiac remodeling. *Intern Med*. 2019;58(14):2023-2030. doi:10.2169/internalmedicine.2035-19
73. Herzog CA, Asinger RW, Berger AK, et al. Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). *Kidney Int*. 2011;80(6):572-586. doi:10.1038/ki.2011.223
74. Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, et al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. *Lancet*. 2013;382(9889):339-352. doi:10.1016/S0140-6736(13)60595-4
75. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. *Am J Kidney Dis*. 2002;39(2 Suppl 1):S1-S266. doi:10.1053/ajkd.2002.30940
76. Shavit L, Lifschitz M, Epstein M. Uremic rats loaded with phosphate show moderate renal failure and high parathyroid hormone, with added features of cardiovascular calcification. *Nephrol Dial Transplant*. 2006;21(8):2240-2247. doi:10.1093/ndt/gfl206
77. Sarnak MJ, Levey AS, Schoolwerth AC, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. *Circulation*. 2003;108(17):2154-2169. doi:10.1161/01.CIR.0000095676.90936.80
78. Herzog CA, Ma JZ, Collins AJ. Long-term outcome of renal transplant recipients in the United States after coronary revascularization procedures. *Circulation*. 2004;109(23):2866-2871. doi:10.1161/01.CIR.0000130677.15085.4F
79. Tonelli M, Wiebe N, Culleton B, et al. Chronic kidney disease and mortality risk: a systematic review. *J Am Soc Nephrol*. 2006;17(7):2034-2047. doi:10.1681/ASN.2005101085
80. Matsushita K, van der Velde M, Astor BC, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. *Lancet*. 2010;375(9731):2073-2081. doi:10.1016/S0140-6736(10)60674-5
81. Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, et al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. *Lancet*. 2013;382(9889):339-352. doi:10.1016/S0140-6736(13)60595-4
82. Matsushita K, Ballew SH, Astor BC, et al. Cohort profile: the Chronic Kidney Disease Prognosis Consortium. *Int J Epidemiol*. 2013;42(6):1660-1668. doi:10.1093/ije/dys173
83. de Zager DJ, Grootendorst DC, Jager KJ, et al. Cardiovascular and noncardiovascular mortality among patients starting dialysis. *JAMA*. 2009;302(16):1782-1789. doi:10.1001/jama.2009.1488
84. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. *Am J Kidney Dis*. 1998;32(5 Suppl 3):S112-S119. doi:10.1053/ajkd.1998.v32.pm9820471
85. Weiner DE, Tighiouart H, Amin MG, et al. Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies. *J Am Soc Nephrol*. 2004;15(5):1307-1315. doi:10.1097/01.ASN.0000123691.46138.E2
86. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. *N Engl J Med*. 2004;351(13):1296-1305. doi:10.1056/NEJMoa041031